

REVIEW

Molecular Regulation of the CNS by Vitamin D

Ludmila MÁČOVÁ¹, Radmila KANCHEVA¹, Marie BIČÍKOVÁ¹

¹Department of Steroids and Proteofactors, Institute of Endocrinology, Prague, Czech Republic

Received August 14, 2023

Accepted October 3, 2023

Summary

Vitamin D is a lipid-soluble vitamin that can be found in some foods. It is also produced endogenously (in the presence of ultraviolet light), transported through the blood to the targets organs and this is the reason to consider vitamin D as a hormone. It is known that vitamin D has genomic and non-genomic effects. This review is focused mainly on the vitamin D receptors, the importance of vitamin D as a neuromodulator, the role of vitamin D in the pathophysiology of devastating neurological disorders such as Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease and the benefit of vitamin D and its derivatives in alleviating these disorders.

Keywords

Vitamin D • Neurosteroids • Brain • Neuroprotection • Neuroinflammation

Corresponding author

Department of Steroids and Proteofactors, Institute of Endocrinology, Národní 8, 110 00 Prague 1, Czech Republic.
E-mail: lmacova@endo.cz

Introduction

It has been observed that the sunlight and warm weather have always been associated with good mood and subjectively better feelings and conversely, the lack of sunshine with physical and mental decline. Without detailed knowledge of the mechanisms of action, some neurological disorders have been treated in the past with phototherapy and vitamin D, by e.g., Aretaeus as early as in the 2nd century AD.

It was later revealed that besides its archetypal role in bone health, vitamin D has been shown to have

positive pleiotropic effects on various levels of human health [1]. Twenty years ago, vitamin D was firstly proposed as a neurosteroid [2] and since then, researches have been amazed at the complexity of molecular mechanisms interacting between vitamin D and neural cells. Developmental, anticancer, antiepileptic, neuro-protective, neuro-immunomodulating, anti-calcification, psychotropic and other observed effects demonstrate the significant role of vitamin D for the brain function and mental health. In animal studies, targeted vitamin D deficiency has led to morphological changes in the brain, in particular a larger volume of lateral ventricles and a smaller cortex thickness [3]. Despite the ever-increasing number of studies concerning the importance of vitamin D in the pathophysiology of neuropsychiatric disorders, the exact cellular mechanism of action remains still unknown. The review focuses on the current knowledge in the field of molecular processes and clinical manifestation that links vitamin D levels and neurological functions.

Genomic and non-genomic effects of vitamin D

Vitamin D synthesis - Location, enzymatic apparatus

Since the discovery of photosynthesis of pre-vitamin D in human skin in the eighties [4], the major metabolic pathway leading to biologically active vitamin D has been described in detail many times, e.g. [5]. In brief, there are two sources of vitamin D: cholecalciferol (vitamin D₃) produced in the cutaneous tissue of animals, and ergocalciferol (vitamin D₂) synthesized in plants. In liver, they both undergo first hydroxylation at position 25 to create calcidiol (25(OH)D). Then, in the kidney, the second hydroxylation at position 1 is performed by the

action of 1 α -hydroxylase (CYP27B1) to produce hormonally active calcitriol (1,25(OH)₂D). However, other tissues, including the brain are known to express CYP27B1 and other apparatus necessary for the local production of calcitriol [6]. Since both calcidiol as well as calcitriol can cross the blood-brain barrier [7], autocrine and paracrine regulation of calcitriol production from circulating calcidiol has been suggested [8]. It appears that the major calcitriol production and production in non-renal tissues may be significantly independent processes.

Vitamin D receptors

In terms of structural properties, vitamin D belongs to the group of steroid hormones with all the analogies that this entails. It is synthesized in endocrine tissue, from where it is transported in cooperation with binding proteins (vitamin D binding protein-VDBP or albumin) through the blood stream to target organs. The effects of vitamin D are mediated through the vitamin D receptor (VDR), which belongs to the nuclear steroid/thyroid receptor superfamily.

Vitamin D exerts biological action *via* both genomic and non-genomic actions. "Classic" genomic effects (in the order of hours to days) act through nuclear VDR, which, after the activation and formation of a heterodimeric complex with the retinoid-X-receptor (RXR), binds to promoter sequences in DNA called Vitamin D response elements (VDREs) and serves as modulator of gene transcription. It has been discovered that thousands of VDR binding sites and hundreds of genes are modulated in this way [9]. In contrast, rapid non-genomic effects of vitamin D alter numerous membrane-mediated signaling pathways involving opening of ion channels, the induction of second messengers (Ca²⁺, cyclic AMP, fatty acids and phosphatidylinositol 3-phosphate) and activation of signaling molecules, such as phospholipase C (PLC) and phospholipase A2 (PLA2), phosphatidylinositol-3 kinase (PI3K) and p21 ras protein, together with protein kinases, specifically protein kinase A (PKA), tyrosine-protein kinase Src, mitogen-activated protein kinases (MAPK), protein kinase C (PKC) and Ca²⁺-calmodulin kinase II (CaM kinase II) and others as discussed in detail elsewhere [10].

It remains a matter of debate which form of vitamin D receptors is involved in non-genomic actions. Nemere and colleagues identified a specific membrane binding protein for 1 α ,25-dihydroxyvitamin D₃

(biologically active form of vitamin D) that rapidly triggers Ca²⁺ transport across the membrane [11]. This receptor was later described as a membrane-associated rapid response steroid (MARRS) binding protein and detailed structural characteristics revealed that this protein was already known from other systems and names e.g., protein disulfide isomerase, family A, member 3 (Pdia3), thioredoxin-like protein or glucose responsive protein 58 kDa (GRP58) and endoplasmic reticulum protein 57/60 kDa (ERp57 or ERp60) [10,12,13]. Intensive molecular studies on the regulation of the genomic and non-genomic effects of vitamin D show that these mechanisms are complex on many levels. The nuclear VDR is likely to be also involved in non-genomic effects, at least for some signaling pathways. It has been revealed that nuclear VDR occurs not only in the cell nucleus but also in caveolae-enriched plasma membranes and perinuclear area. Both Pdia3 and nuclear VDR bind caveolin-1, a scaffolding protein whose knocked down expression led to the loss of genomic as well as non-genomic actions of vitamin D [14].

The VDR is present in numerous brain cells such as oligodendrocytes, astrocytes, microglia, and neurons [6]. Furthermore, the extensive Genotype-Tissue Expression (GTEx) project revealed the expression of the VDR in all 11 studied regions within human brain including cerebral cortex, cerebellum, amygdala, anterior cingulate cortex, caudate (basal ganglia), hippocampus, hypothalamus, nucleus accumbens, putamen, spinal cord, and pituitary gland, with the highest abundance in the hypothalamus [15]. Receptor localization indicates responsive regions of its effector, so it is possible to deduce significant roles of vitamin D in areas where VDR is expressed.

Vitamin D as a mediator

In the following paragraphs, factors that participate in the proper functioning of the nervous system are mentioned. They have been reported to be modulated by active vitamin D and their dysregulation may lead to the development of neuropathological conditions.

Neurotransmitters

Catecholamines

Vitamin D deficiency is often associated with altered neurotransmission, while dopamine (DA) being the most commonly reported. DA plays several regulating

roles especially as a major component of reward-motivated behavior but also in motor control, executive and arousal functions mediated *via* activation of dopaminergic receptors in substantia nigra, ventral tegmental area, and arcuate nucleus of the hypothalamus within the human brain. The importance of vitamin D on the dopaminergic system was discovered in the 1980s [16] and has been evidenced by several observations. First, the VDR expression has been detected in both rodent as well as human developing dopamine neurons [17]. Second, a study on experimental neuronal model has shown that VDR and 1,25(OH)₂D₃ are directly involved in regulating the expression of dopaminergic-associated genes resulting in increasing DA neuron differentiation, tyrosine hydroxylase (TH) expression (the rate-limiting enzyme in dopamine synthesis), increasing DA production and decreasing the expression of NEUROG2 a marker of immature DA neurons [18]. Vitamin D has been also shown to alter the gene expression of key factors necessary for the physiological differentiation and maturation of DA neurons such as Nurr1 or p57Kip2 [19,20]. Furthermore, maternal vitamin D treatment increased the expression of factors Lmx1a, Nurr1 and TH in individual mesencephalic DA cells, restored normal DA positioning and thus prevented the development of abnormal dopaminergic phenotypes in mouse offspring [21]. Third, the developmental vitamin D deficiency (DVD) has been shown to directly modulate metabolic pathways resulting in reduced DA biosynthesis and turnover [22].

It is of note that developmental changes in dopaminergic signalization due to vitamin D deficiency did not occur equally in all parts of the neonatal rat brain, which may produce inconsistent results [23].

Glutamate/GABA–glutamatergic system

Another signaling system affected by vitamin D uses the major excitatory and inhibitory neurotransmitters - glutamate and GABA (γ -aminobutyric acid) - and their common precursor glutamine. Vitamin D deficient adult mice produced a reduction in glutamate decarboxylase 65/67, the enzymes involved in GABA synthesis. In addition, immunodeficient laboratory mice reported decreased brain levels of glutamate and glutamine and elevated levels of GABA when fed by a vitamin D deficient diet [22]. Another study by the same research group confirmed that developmental deficiency of vitamin D induces decreased levels of glutamine ubiquitously across the brain supporting impairments in

glutamate signaling and/or energy metabolism [23].

It is not yet known whether vitamin D directly binds and modulates N-methyl-D-aspartate (NMDA) receptors, a ligand-gated calcium channels regulated by glutamate. However, a study on neurotransmitter receptors revealed reduced expression of the NMDA receptor subunit after vitamin D administration, which contributes to the protective effect of vitamin D against neurotoxicity [24]. Vitamin D partially inhibited NMDA and kainate receptor mediated actions as demonstrated on juvenile gonadotrophin-releasing hormone (GnRH) neurons [25].

In fetal growth restriction rats (FGR) the cognitive function was effectively perfected after 30 days of vitamin D supplementation and the learning and memory ability was also significantly improved. Moreover, the mRNA and protein relative expression of NRI subunit of the NMDA receptor in hippocampus of FGR rats was significantly higher after vitamin D administration than that in the control group [26].

Serotonin

Neurotransmitter serotonin (5-hydroxytryptamine) affects numerous physiological processes in human body including sleep, learning, memory, pain, mood, social behavior, parenting and many others. Selective serotonin reuptake inhibitors are a class of drugs that are broadly used as antidepressants when treating major depressive and anxiety disorders, and other psychological conditions. The synthetic pathway of serotonin derives from the amino acid L-tryptophan and the rate-limiting enzyme of the biosynthesis is tryptophan hydroxylase (TPH) when type 1 (TPH1) is localized in peripheral “non-brain” tissues and tryptophan hydroxylase type 2 (TPH2) is neuron-specific [27]. It has been revealed that vitamin D affects serotonin metabolism by potentiating TPH2 gene expression in human as well as experimental model [28] and inhibit expression of peripheral TPH1 so that less serotonin outside and more serotonin in brain is produced [29,30]. In addition to TPH, vitamin D also alters the expression of the enzyme responsible for the serotonin breakdown - monoamine oxidase (MAO), which increases the concentration of 5-hydroxyindoleacetic acid (5-HIAA), the key degradation metabolite of serotonergic pathway [31]. The 5-HIAA was significantly increased in brains of vitamin D deficient mice compared to controls. Also, the serotonin/5-HIAA ratio pointed to increased serotonin turnover in connection with vitamin D deficiency [22].

The impacts of vitamin D deficiency on serotonergic system explains some pathophysiological conditions such as autism [32], sleep and mood disorders [33].

Acetylcholine

The cholinergic system in the brain plays a key role in modulating sensory and motor functions along with cognitive behavior through the regulation of acetylcholine receptors. Two enzymes, choline acetyltransferase (ChAT) and acetylcholinesterase (AChE), are essential in assessing cholinergic transmission. Whereas ChAT is an enzyme responsible for the synthesis of the neurotransmitter acetylcholine, AChE is an enzyme that catalyzes the breakdown of acetylcholine and some other choline esters that function as neurotransmitters.

The importance of vitamin D in the regulation of the cholinergic system has been confirmed in several studies, especially in experimental animals with a previous disorder of cholinergic signaling. In diabetic animal models, the ChAT activity has been observed to be significantly decreased while the AChE activity has been significantly increased compared to non-diabetic control. Diabetes-induced alterations in enzyme activity were mitigated by vitamin D3 supplementation and the neuroprotective effect of vitamin D supplementation on cognitive function in diabetic animals was attributed to the enhancing prefrontal cortex cholinergic transmission [34]. In another study, a six-month vitamin D substitution reversed neuropathological processes caused by a high-fat diet in Wistar rats and supported the potential effect of vitamin D on recognition memory and cholinergic transmission [35]. Additionally, the administration of vitamin D to animals with streptozotocin-induced sporadic Alzheimer's type dementia resulted in the prevention of increased AChE activity [36]. As hypothyroidism was significantly associated with an overactivity of AChE, treatment with vitamin D alleviated the enzymes activity and recovered hypothyroidism-induced cognitive impairment and improved memory performance [37].

In addition to affecting the enzymatic activity involved in acetylcholine metabolism, vitamin D has also been shown to restore altered cholinergic receptor gene expression towards normalization in diabetic rats [38].

Ion channels

Calcium ion (Ca^{2+}) is an essential intracellular agent for communication and triggering signaling

pathways. Inside the cell, the calcium ion functions as an allosteric modulator of proteins and enzymes or as a second messenger in signal transduction. In neurons, in addition to the role of an intracellular signaling mediator, calcium also plays the role of a charge carrier. Calcium signaling is involved in various physiological processes such as neurotransmitter release, apoptosis and maintenance of membrane excitability. Calcium homeostasis is crucial for proper neuronal function, and dysregulation toward elevated intracellular calcium leads to calcium-induced brain neurotoxicity [39] and can be the cause of various neurological disorders including amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease and others [40].

L-type voltage-gated calcium channels (L-VSCCs)

One type of calcium channel reported to be modulated by active vitamin D is the L-type voltage-gated calcium channel. Evidence indicates that several mechanisms are involved in the regulation of calcium balance by vitamin D in terms of reduces Ca^{2+} signaling.

Treatment with vitamin D reduces both L-VSCC activity and expression of subunits forming the L-type channel in brain neurons [41]. On the contrary, vitamin D deficient rats exhibits dysregulated calcium regulating genes expression, including a voltage dependent anion channel 1 (VDAC-1) which is the major calcium ion transport channel [42]. Calcitriol deficient mice with knockout 1α -hydroxylase showed an increase in the expression of L-type voltage-gated calcium channel [43]. Moreover, the expression of LVSCC-A1C protein was enhanced when VDR was down-regulated, again providing evidence for vitamin D's ability to regulate calcium ion channels [44].

Recent studies show that in addition to the aforementioned genomic actions vitamin D also affects calcium ion channels by means of fast actions non-genomically, without the participation of gene expression. $1,25(\text{OH})_2\text{D}$ is able to non-genomically modulate L-VGCC activity in a subset of neurons in the developing mouse brain [45].

Transient receptor potential cation channel subfamily V member 1 (TRPV1)

TRPV1, also known as capsaicin receptor or vanilloid receptor 1 plays a role in nociception and belongs to the group of ion channels with the ability to control intracellular calcium. Both 25OHD and $1,25(\text{OH})_2\text{D}$ can directly (but weakly) activate TRPV1

yet antagonize the stimulatory effects of the capsaicin and oleoyl dopamine. The physiological manifestation of vitamin D effects may result in TRPV1-mediated calcium entry into neurons suggesting vitamin D may temper nociceptive pain signaling pathways [46].

Plasma membrane pumps and exchangers

Another mechanism of action of vitamin D is an increase in the expression of the plasma membrane Ca^{2+} pump (PMCA) and the sodium/ Ca^{2+} exchanger 1 (NCX1) via the activated VDR [47].

Voltage-gated chloride channels

To date, a handful of studies have described triggering voltage-gated chloride channel by calcidiol and calcitriol. Sertoli and kidney cells were used in these studies [48,49]. However, it remains to be clarified whether a similar mechanism also operates in human neurons.

The aforementioned findings confirm that calcium homeostasis is crucial for the proper development and functioning of the nervous system. As vitamin D interferes with calcium signaling, vitamin D deficiency may disrupt calcium signaling and may result in various neurodegenerative disorders [32].

Calcium-binding proteins

Vitamin D treatment may protect against neurotoxicity and calcium-mediated destruction also through the upregulation of calcium-binding proteins. In vivo study, vitamin D increased expression of calbindin-D28K and parvalbumin [50].

Neurotrophins

The neurotrophins and neurotrophic factors includes a family of proteins that regulate neural development, survival, function and plasticity as reviewed e.g. by Huang and Reichardt [51]. Since the early 1990s, when 1,25(OH) $_2$ D $_3$ was first described as a possible inducer of nerve growth factor [52], it has been shown that vitamin D significantly interferes with the function of the nervous system through the modulation of diverse neurotrophins.

Nerve growth factor (NGF)

Nerve growth factor is well recognized as a regulatory protein facilitating cell differentiation and survival, neurite outgrowth, and apoptosis prevention in target neurons. In the aforementioned study [52],

1,25(OH) $_2$ D $_3$ was revealed to increase the expression of NGF in murine fibroblasts, which resulted in an increased concentration of this biomolecule in the culture cells medium. Papers that were subsequently published demonstrated a similar stimulating effect of active vitamin D on the NGF expression in primary cultures of glial cells [53], astrocytes [54], Schwann cells [55], neurons [56] or even *in vivo* in animal brains [57]. Accordingly, reduced NGF production was observed in 1,25(OH) $_2$ D $_3$ lacking mice brains [43] and the disruption of NGF production that may result in higher vulnerability to aging and neurodegeneration was observed when VDR was suppressed [44].

Brain-derived neurotrophic factor (BDNF)

The brain-derived neurotrophic factor is a key protein involved in neuronal growth and maintenance, a regulator of neurotransmitters and neuroplasticity related to memory and learning. Available studies have shown that vitamin D supplementation significantly raised BDNF in non-differentiated neural stem cells [58], in adult [59,60] as well as aging [61] experimental brains. Prenatal vitamin D deficiency leads to reduced BDNF [62]. In addition, a direct positive association between serum vitamin D and BDNF concentrations has recently been observed in humans [63].

However, it should be noted that the effect of vitamin D on BDNF production is not consistent across all neural cell types. Increased BDNF expression after vitamin D application could not be demonstrated, for example, in astrocyte cells [64].

Neurotrophin 3 (NT-3) and Neurotrophin 4 (NT-4)

Neurotrophins are protein-based agents supporting the survival and differentiation of existing neurons and stimulating neurogenesis. Both NT-3 and NT-4 can be regulated by active vitamin D. After vitamin D stimulation, increased expression of the NT-3 was observed in multiple nerve cell types and tissues [58,64,65], while NT-4 was down-regulated, at least in astrocytes [64].

p75 neurotrophin receptor (p75NTR)

The p75NTR receptor was first described as a nerve growth factor receptor fifty years ago [66]. It was much later that p75NTR was shown to function as a receptor for other neurotrophic factors including NGF, BDNF, NT-3 and NT-4 [67,68].

In addition to regulating the expression of

neurotrophins, alone vitamin D also interferes with the expression of the receptor for neurotrophins. The active hormone raised the abundance of the mRNA the low-affinity neurotrophin receptor (the p75NTR protein) in rat oligodendrocytes [69] and on the contrary, reduced expression of p75NTR was observed in newborn rats of vitamin D-deficient mothers [3]. However, it has also been shown that such modulation by vitamin D is most likely site and cell type specific [70].

Neurotrophic factors

Glial cell line-derived neurotrophic factor (GDNF)

A relatively small protein GDNF is highly produced throughout both the central and peripheral nervous system. The main feature of GDNF is the trophic effect especially on dopaminergic and motor neurons. Meanwhile, it is also involved in the processes of survival and differentiation of neurons. Calcitriol has been observed to be a potent inducer of GDNF expression in multiple studies [58,71-73]. In another study, a significant reduction in brain content of GDNF has been also described in rats born to vitamin D-deficient mothers [3]. It should be noted that data were contradictory when taking into account studies of different parts of the brain [74] or *in vivo* studies [75], these studies did not observed a significant effect of calcitriol on GDNF.

For completeness, it would be noted that other members of the GDNF family were hardly examined at all. Vitamin D-deficiency has been shown to reduce neurturin (NTN)-immunoreactive cells [76], while to the best of authors' knowledge, the effect of vitamin D on the proteins artemin (ART) and persephin (PSP) has not been reported so far.

Ciliary neurotrophic factor (CNTF)

In nervous system CNTF instigates neurotransmitter production, neurite outgrowth and is also relevant in neuronal survival. Almost nothing is known about the relationship between vitamin D and CNTF. Only a single study reported that 1,25(OH)₂D₃ promotes increased expression of CNTF in neural stem cells [58].

Growth factors and related proteins regulated by 1,25-dihydroxyvitamin D₃

Insulin-like growth factor 1 (IGF-1)

This regulatory protein is predominantly produced in the liver with the highest production rate during puberty and the lowest in infancy and elderly. Its

main function is to regulate childhood growth and anabolic effects in adults. With regard to vitamin D, the finding that 1,25(OH)₂D₃ and its analogue enhanced expression of IGF-1 Schwann cells is of key importance [77]. Furthermore, mRNA expression levels of IGF-1 were significantly higher when vitamin D was supplemented to aged rats compared to animals with no vitamin D supplementation [78]. Moreover, the suppression of renal catabolic enzyme vitamin D 24-hydroxylase was observed in IGF-1 treated rats [79]. The reciprocal regulation of IGF-1 and 1,25(OH)₂D₃ was summarized by Gómez. While 1,25(OH)₂D₃ has been shown to promote the action of IGF-1 by increasing IGF-1 receptors, IGF-1 increases 1,25(OH)₂D₃ concentrations by stimulating the hydroxylation of 25(OH)D₃ to produce the active 1,25(OH)₂D₃ hormone [80].

Fibroblast growth factor (FGF)

This large family of regulatory proteins is produced in macrophages with effects extending into the nervous system. Active vitamin D significantly interferes with the regulation of fibroblast growth factor-23 (FGF-23). The supply of 1,25(OH)₂D increases FGF23 levels [81], subsequently, high levels of FGF23 lead to a reduction in 1,25(OH)₂D through a negative feedback mechanism [82]. Additionally, reduced expression of *Fgf-23* gene was observed in VDR-knockout mice [83].

Klotho protein

Klotho gene has been recognized as an aging suppressor gene that encodes a multifunctional protein participating in processes of the insulin and Wnt signaling, oxidative stress suppression, and maintaining phosphatase and calcium homeostasis [84]. Three main functions have been recognized in regard to klotho. A hormonal function, an enzymatic and a signaling function as an obligatory co-receptor for FGF23 [85]. 1,25(OH)₂D₃ induces klotho gene expression in kidney and the loss of klotho protein results in up-regulation of 1,25(OH)₂D₃ synthesis [86].

Epidermal growth factor (EGF)

To our knowledge, the effect of active vitamin D on epidermal growth factor (EGF) levels has not yet been reported. However, an effect on its receptor EGFR has been described. Quantification of changes in protein levels revealed, among other findings, higher expression of the EGFR was induced by vitamin D in human brain

stem cells [87]. Vitamin D regulation of EGFR is likely cell and/or tissue specific as EGFR gene was suppressed by 1,25(OH)2D3 e.g., in human ovarian cancer cells [88].

Neuregulin (NRG)

Neuregulins are a group of structurally similar signaling proteins related to the EGF family. They have various functions on the nervous system, especially during the development of neurons and the formation of neuromuscular synapses. Although the molecular mechanism of clinical manifestations has not yet been fully elucidated, it has been observed that vitamin D concentration positively affects NGR1 in the blood samples of schizophrenic patients [89].

Transforming growth factor (TGF)

It is a group of relatively small regulatory proteins with cytokine-like function. Changes induced by TGF mainly affect embryonic development, differentiation and proliferation, regulation of the endocrine and immune systems. It has been shown that 1,25(OH)2D3 diminishes the expression of proto-oncogenes and potentiates transforming growth factor (TGF- β 2) expression in neuroblastoma cells [90].

Other signaling proteins

Forkhead box protein P2 (Foxp2)

This protein is crucial for proper development of language and ability to speak in humans [91]. Prenatal vitamin-D deficiency resulted in significant alteration in Foxp2 expression and reduced Foxp2 immunoreactive cells in the developing cortex in vitamin D-deficient rodent fetuses [62].

Microtubule associated protein (MAP), growth-associated protein (GAP) and synapsin

While the first two mentioned are involved in the proper growth, maintenance of stability and plasticity of neurons, synapsins are responsible for the regulation on neurotransmitters from vesicles at synapses. Vitamin D3 administration resulted in increased expression of all microtubule-associated protein-2 (MAP2), growth-associated protein-43 (GAP43) and synapsin-1 in rat cortical neurons suggesting its role in differentiation and maturation processes [92,93]. The tubulin associated unit proteins (Tau) relate to the MAP family. They are mainly present in neurons, where they ensure stability of axonal microtubules. Excessively phosphorylated Tau proteins (p-Tau) are formed to neurofibrillary tangles (NFTs)

which are one of the hallmarks of Alzheimer's disease. With respect to vitamin D, treatment with vitamin D or its analogue decreased hyperphosphorylation of tau protein in experimental rats [94,95].

Amyloid beta protein (A β)

Amyloid beta is a relatively small peptide of 39-43 amino acids, which is formed by cleavage of amyloid precursor protein (APP). Its normal physiological function remains unclear, but the accumulated product A β is deposited in amyloid plaques [96], a key pathological feature in Alzheimer's patients.

Vitamin D has been shown to be related to the amyloids in numerous studies. Importantly, even a mild vitamin D hypovitaminosis significantly increased A β , which was mainly caused by the regulation of the enzymatic apparatus involved in APP cleavage [97]. Other studies supported the importance of vitamin D by finding that vitamin D administration led to a reduction in A β -related biomarkers and induce the clearance in animal models [94,98] as well as Alzheimer's patients [99].

Alpha-synuclein (α -Syn)

This neuronal protein is responsible for proper synaptic function and neurotransmitter release. Under pathological condition α -Syn may change conformation to form insoluble aggregates or filaments. Synucleinopathies are manifested in various neurodegenerative diseases, mainly Parkinson's disease but also an α -Syn fragment, known as the non-amyloid beta component (NAC) in Alzheimer's disease.

With regard to alpha synuclein, the neuroprotective significance of vitamin D and its analogues is based in the inhibition of the early α -Syn aggregation [100,101].

Nuclear receptor related 1 protein (NURR1)

In humans, NURR1 is critical for DA system in the brain and its disruption results in disorders related to DA dysfunction, including Parkinson's disease, schizophrenia, autism, and manic depression.

Prenatal vitamin D deficiency resulted in reduced Nurr1 expression in developing rat brains [20] and conversely, vitamin D treatment increased the expression of Nurr1 (and TH) in individual mesencephalic DA cells and restored normal positioning [21].

Neural cadherin (N-cadherin, cadherin-2)

Neural cadherin, like other cadherins, ensures

cell to cell adhesion. In addition, it also ensures interactions between interconnected cells *via* its extracellular domain. In neurons, loss of protein function causes dysregulation of synaptic communication, differentiation DA neurons which clinically manifest which is clinically manifested by learning and memory impairment or hyperactivity.

Whereas developmental vitamin D deficiency decreased N-cadherin expression [75], vitamin D treatment upregulated N-cadherin [102].

Neuroinflammation markers

Neuroinflammation is a key process for neurodegeneration and associated neuronal loss which manifest as numerous neurodegenerative disorders such as multiple sclerosis, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis and others. Activated microglia produce diverse pro-inflammatory factors including cytokines and neurotoxic agents.

In numerous reported studies, vitamin D suppresses inflammatory processes by down-regulation of pro-inflammatory interferon gamma (IFN- γ), tumor necrosis factor alpha (TNF- α), granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin 1 β (IL-1 β), interleukin 6 (IL-6), interleukin 17A (IL-17A) and inducible nitric oxide synthase (iNOS) as well as up-regulation of anti-inflammatory interleukin 4 (IL-4), interleukin 10 (IL-10) and interleukin 34 (IL-34) [103-107].

Markers of oxidative stress

Oxidative stress is considered an imbalance between arising reactive oxygen species (ROS) and antioxidant capacity of the cell to remove these harmful substances. Oxidative stress causes serious cell damage at the DNA level and accompanies many neurodegenerative and cancer diseases.

Vitamin D protects against oxidative stress by activating the antioxidant enzymes, the superoxide dismutase (SOD) and catalase (CAT) [59,108]. In addition, vitamin D elevates thiol content and decreased nitrite and malondialdehyde (MDA) concentration [59]. Calcitriol also induces upregulation of glutathione (GSH) production, which also contributes to the antioxidant effect of vitamin D rat astrocytes [109].

Vitamin D deficiency in developing vs. adult brain

As it implied the above, vitamin D deficiency

may result in the development of various neurodegenerative diseases. However, the effect depends on the level of maturation of the nervous system.

Vitamin D deficiency in developing brain

A number of comprehensive reviews have been published summarizing the effect of vitamin D deficiency on the developing brain. Based on animal models, altered neuronal differentiation, neuroinflammation, neurodegeneration, protein expression and metabolic changes leading to brain structural changes should be mentioned among the main mechanisms [110].

Vitamin D deficiency in adult brain

It is supposed that vitamin D deficiency in adulthood does not impact on cell proliferation, differentiation or neuronal apoptosis, but factors such as increased oxidative stress, reduced neuroprotection and disbalance in neurotrophic factors result in disrupted cognition and higher vulnerability to adverse brain conditions [111].

Clinical outcomes of vitamin D deficiency

Many neuropathological disorders share similar pathophysiological mechanisms, e.g., increased inflammation, oxidative stress, neurodegeneration, mitochondrial dysregulation, and apoptosis. These unfavorable conditions also include a vitamin D deficiency as a risk factor for the development of the disease. Such disorders include multiple sclerosis (MS), Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).

In the Table 1, we would like to outline the neuropathologies in which vitamin D deficiency has been observed as a significant risk factor. A number of these diseases have already been described in detail, including the role of vitamin D in the disease. For this reason, we do not explain the background and exact mechanism of the disease development in our review. The table merely summaries a brief overview (in alphabetical order) with references to relevant and up-to-date sources where possible.

Pharmacological application of vitamin D in neurodegenerative diseases

Considering the pluripotent character of the effects, the use of vitamin D and its artificial analogues are considered to be useful a tool in the treatment of

Table 1. Neuropathologies related to vitamin D deficiency.

Pathology	Involved element	Adverse condition	Reference
<i>ADHD</i>	BDNF, DA, serotonin	Neuroinflammation, oxidative stress	[116]
<i>ALS</i>	IGF-1, GDNF, SOD-1, Ca ²⁺ homeostasis	Excitotoxicity, oxidative stress	[117]
<i>ASD</i>	Ca ²⁺ homeostasis, DA, serotonin, GABA/glutamate	Neuroinflammation, mitochondrial dysfunction, oxidative stress	[32]
<i>AD</i>	p-Tau, A β , NGF, BDNF, GDNF, TGF- β , IGF-1, IL-1, IL-6, TNF- α	Neuroinflammation, cholinergic deficits, synaptic loss, and oxidative stress	[118]
<i>Cancer</i>	Cyclin-dependent kinases, TNF- α , Ca ²⁺ homeostasis, p75NTR, NGF, NT-3, GDNF	Oxidative stress, Dysregulated proliferation, apoptosis, migration	[119]
<i>Epilepsy</i>	GABA/glutamate, NMDA, L-VSCC, Ca ²⁺ homeostasis, TGF- β , NO, IL-1 β , IL-6, IL-8, TNF- α , IFN- γ	Neuroinflammation, oxidative stress	[118]
<i>(Generalized) anxiety disorder</i>	GABA/glutamate, serotonin, DA, GSH	Neuroinflammation, oxidative stress	[120]
<i>Huntington's disease</i>	GABA, BDNF, NGF, CAT	Neuroinflammation, mitochondrial dysfunction, oxidative stress	[121]
<i>Depression</i>	Ca ²⁺ homeostasis, PMCA, L-VSCC, GABA/glutamate, serotonin, DA, TNF- α , IL-1 α , IL-1 β , IL-6, GSH	Excitotoxicity, neuroinflammation, oxidative stress	[122]
<i>MS</i>	IFN- γ , IL-1 β , IL-2, IL-6, IL-12, TNF- α , NO	Neuroinflammation, oxidative stress, neuronal demyelination	[118]
<i>Neurocognitive decline (mild)</i>	L-VSCC, NGF, GDNF, NO	Neuroinflammation, oxidative stress	[123]
<i>Neuromyelitis Optica</i>	IFN- γ , Ig, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17	Neuroinflammation	[124]
<i>Pain</i>	TRPV, VDR, NGF, EGFR, GDNF	Cellular signal transduction, activity and survival of proprioceptive neurons	[114]
<i>PD</i>	L-VSCC, GDNF, NGF, DA, TH, MANF, CDNF, α -synuclein, NO, IL-1 β , IL-17, TNF- α , IFN- γ	Neuroinflammation, mitochondrial dysfunction, oxidative stress, excitotoxicity, neurodegeneration of DA neurons	[118]
<i>Seasonal affective disorder</i>	Serotonin, melatonin, DA	Impaired neurotransmission	[125]
<i>Schizophrenia</i>	DA, GABA/glutamate, acetylcholine, N-cadherin, NRG1, NF- κ B, IL-1 β	Impaired neurotransmission, neuroinflammation	[126]
<i>Sleep deprivation and RLS</i>	Melatonin, serotonin, DA, GABA, N-cadherin	Impaired neurotransmission	[127]
<i>Stress</i>	Cortisol, melatonin, NE, IL-1 β , IL-6, TNF- α , IFN- γ	Neuroinflammation	[128]
<i>Cerebrovascular Diseases</i>	Ca ²⁺ homeostasis, NO, SOD acetylcholine, IL-1, IL-2, IL-6, IL-23, TNF- α , IFN- γ , NF- κ B, cadherin	Oxidative stress, neuroinflammation, cholinergic dysfunction	[129]

Neuroprotective effects of vitamin D




Fig. 1. Schematic review of neuroprotective effects of vitamin D. Factors that are up-regulated are marked in green, factors that are down-regulated are in red.

neurodegenerative diseases. One of the prerequisites for effective treatment is determining the optimal dose for the treatment of neurodegenerative disease while simultaneously avoiding hypervitaminosis (and hypercalcemia) due to overdosing. For that reason, vitamin D analogs capable of activating VDR with reduced calcemic effects seem to be advantageous. Vitamin D and its analogs are being considered for therapy in Alzheimer's disease [112], multiple sclerosis [113], chronic pain [114], ADHD [115] and others, but more research is needed to establish effective and safe dosing.

Concluding remarks

Substantial clinical data reveal that vitamin D may play an important role in the course and amelioration of a number of neuropsychiatric disorders including MS, PD, AD, schizophrenia and more. In the nervous system, 1,25(OH)₂D₃ reduces oxidative stress and inflammation, induces neuroprotection, and up-regulates a wide variety of neurotrophins and neuro-regulative proteins.

The authors have not aimed to provide a complete review, especially since the topic about the wide role of vitamin D is still developing and on the other hand, some areas of research (vitamin D receptors) have already been extensively covered. The goal of the authors has been to focus on the pathways in which vitamin D can interfere with pathophysiological processes in the

nervous system. Some study results reported conflicting data. This may be due to the fact that the regulation by vitamin D is local and tissue specific in many cases. Furthermore, it is shown that both the “classical” genomic way of action with involvement of gene expression and the fast non-genomic pathway work hand in hand, probably synergistically. At the same time, relevant experimental *in vitro* model to study neuropsychiatric condition is yet to be discovered.

Abbreviations

α -Syn, alpha-synuclein; A β , amyloid- β peptide; BDNF, brain-derived neurotrophic factor; CAT, catalase; CDNF, cerebral dopamine neurotrophic factor; CNTF, ciliary neurotrophic factor; DA, dopamine; EGFR, epidermal growth factor receptor; FGF, fibroblast growth factor; FOXp2, forkhead box protein P2; GABA, γ -aminobutyric acid; GAP, growth-associated protein; GDNF, glial cell line-derived neurotrophic factor; GSH, glutathione; Ig, immunoglobulins; IFN- γ , interferon gamma; IGF-1, Insulin-like growth factor 1; IL, interleukins; L-VSCC, L-type voltage-gated calcium channels; MANF, mesencephalic astrocyte-derived neurotrophic factor; MAP, microtubule associated protein; MDA, malondialdehyde; NE, norepinephrine; NCX1, sodium/calcium exchanger 1; NF- κ B, nuclear factor kappa B; NGF, nerve growth factor; NMDA, N-methyl-D-aspartate; NO, nitric oxide; NRG, neuregulin; NT-3, neurotrophin 3; NT-4, neurotrophin 4; NURR1, nuclear

receptor related 1 protein; PMCA, plasma membrane calcium pump; p-Tau, phosphorylated tubulin associated unit proteins; p75NTR, p75 neurotrophin receptor; SOD, superoxide dismutase; TGF, transforming growth factor; TNF- α , tumor necrosis factor α ; TRPV1 transient receptor potential cation channel subfamily V member 1; VDR, vitamin D receptor.

Conflict of Interest

There is no conflict of interest.

Acknowledgements

The study was supported by MH CZ – DRO (Institute of Endocrinology – EÚ, 00023761) and by the grant NU20-04-00450.

References

1. Wimalawansa SJ. Non-musculoskeletal benefits of vitamin D. *J Steroid Biochem Mol Biol* 2018;175:60-81. <https://doi.org/10.1016/j.jsbmb.2016.09.016>
2. McGrath J, Feron F, Eyles D, Mackay-Sim A. Vitamin D: the neglected neurosteroid? *Trends Neurosci* 2001;24:570-572. [https://doi.org/10.1016/S0166-2236\(00\)01949-4](https://doi.org/10.1016/S0166-2236(00)01949-4)
3. Eyles D, Brown J, Mackay-Sim A, McGrath J, Feron F. Vitamin D3 and brain development. *Neuroscience* 2003;118:641-653. [https://doi.org/10.1016/S0306-4522\(03\)00040-X](https://doi.org/10.1016/S0306-4522(03)00040-X)
4. Holick MF, MacLaughlin JA, Clark MB, Holick SA, Potts JT, Jr., Anderson RR, Blank IH, Parrish JA, Elias P. Photosynthesis of previtamin D3 in human skin and the physiologic consequences. *Science* 1980;210:203-205. <https://doi.org/10.1126/science.6251551>
5. Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. *Physiol Rev* 2016;96:365-408. <https://doi.org/10.1152/physrev.00014.2015>
6. Landel V, Stephan D, Cui X, Eyles D, Feron F. Differential expression of vitamin D-associated enzymes and receptors in brain cell subtypes. *J Steroid Biochem Mol Biol* 2018;177:129-134. <https://doi.org/10.1016/j.jsbmb.2017.09.008>
7. Pardridge WM, Sakiyama R, Coty WA. Restricted transport of vitamin D and A derivatives through the rat blood-brain barrier. *Journal of neurochemistry* 1985;44:1138-1141. <https://doi.org/10.1111/j.1471-4159.1985.tb08735.x>
8. Mayne PE, Burne THJ. Vitamin D in Synaptic Plasticity, Cognitive Function, and Neuropsychiatric Illness. *Trends Neurosci* 2019;42:293-306. <https://doi.org/10.1016/j.tins.2019.01.003>
9. Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. *Chem Biol* 2014;21:319-329. <https://doi.org/10.1016/j.chembiol.2013.12.016>
10. Hii CS, Ferrante A. The Non-Genomic Actions of Vitamin D. *Nutrients* 2016;8:135. <https://doi.org/10.3390/nu8030135>
11. Nemere I, Dormanen MC, Hammond MW, Okamura WH, Norman AW. Identification of a specific binding protein for 1 α ,25-dihydroxyvitamin D3 in basal-lateral membranes of chick intestinal epithelium and relationship to transcaltachia. *J Biol Chem* 1994;269:23750-23756. [https://doi.org/10.1016/S0021-9258\(17\)31579-X](https://doi.org/10.1016/S0021-9258(17)31579-X)
12. Doroudi M, Schwartz Z, Boyan BD. Membrane-mediated actions of 1,25-dihydroxy vitamin D3: a review of the roles of phospholipase A2 activating protein and Ca(2+)/calmodulin-dependent protein kinase II. *J Steroid Biochem Mol Biol* 2015;147:81-84. <https://doi.org/10.1016/j.jsbmb.2014.11.002>
13. Fleet JC. Rapid, membrane-initiated actions of 1,25 dihydroxyvitamin D: what are they and what do they mean? *J Nutr* 2004;134:3215-3218. <https://doi.org/10.1093/jn/134.12.3215>
14. Chen J, Doroudi M, Cheung J, Grozier AL, Schwartz Z, Boyan BD. Plasma membrane Pdia3 and VDR interact to elicit rapid responses to 1 α ,25(OH)(2)D(3). *Cell Signal* 2013;25:2362-2373. <https://doi.org/10.1016/j.cellsig.2013.07.020>
15. Carithers LJ, Ardlie K, Barcus M, Branton PA, Britton A, Buia SA, Compton CC, DeLuca DS, Peter-Demchok J, Gelfand ET, Guan P, Korzeniewski GE, Lockhart NC, Rabiner CA, Rao AK, Robinson KL, Roche NV, Sawyer SJ, Segrè AV, Shive CE, Smith AM, Sobin LH, Undale AH, Valentino KM, Vaught J, Young TR, Moore HM. A Novel Approach to High-Quality Postmortem Tissue Procurement: The GTEx Project. *Biopreserv Biobank* 2015;13:311-319. <https://doi.org/10.1089/bio.2015.0032>

16. Baksi SN, Hughes MJ. Chronic vitamin D deficiency in the weanling rat alters catecholamine metabolism in the cortex. *Brain research* 1982;242:387-390. [https://doi.org/10.1016/0006-8993\(82\)90331-6](https://doi.org/10.1016/0006-8993(82)90331-6)
17. Cui X, Pelekanos M, Liu PY, Burne TH, McGrath JJ, Eyles DW. The vitamin D receptor in dopamine neurons; its presence in human substantia nigra and its ontogenesis in rat midbrain. *Neuroscience* 2013;236:77-87. <https://doi.org/10.1016/j.neuroscience.2013.01.035>
18. Pertile RA, Cui X, Eyles DW. Vitamin D signaling and the differentiation of developing dopamine systems. *Neuroscience* 2016;333:193-203. <https://doi.org/10.1016/j.neuroscience.2016.07.020>
19. Cui X, Pelekanos M, Burne TH, McGrath JJ, Eyles DW. Maternal vitamin D deficiency alters the expression of genes involved in dopamine specification in the developing rat mesencephalon. *Neurosci Lett* 2010;486:220-223. <https://doi.org/10.1016/j.neulet.2010.09.057>
20. Luan W, Hammond LA, Cotter E, Osborne GW, Alexander SA, Nink V, Cui X, Eyles DW. Developmental Vitamin D (DVD) Deficiency Reduces Nurr1 and TH Expression in Post-mitotic Dopamine Neurons in Rat Mesencephalon. *Mol Neurobiol* 2018;55:2443-2453. <https://doi.org/10.1007/s12035-017-0497-3>
21. Luan W, Hammond LA, Vuillermot S, Meyer U, Eyles DW. Maternal Vitamin D Prevents Abnormal Dopaminergic Development and Function in a Mouse Model of Prenatal Immune Activation. *Sci Rep* 2018;8:9741. <https://doi.org/10.1038/s41598-018-28090-w>
22. Groves NJ, Kesby JP, Eyles DW, McGrath JJ, Mackay-Sim A, Burne TH. Adult vitamin D deficiency leads to behavioural and brain neurochemical alterations in C57BL/6J and BALB/c mice. *Behav Brain Res* 2013;241:120-131. <https://doi.org/10.1016/j.bbr.2012.12.001>
23. Kesby JP, Turner KM, Alexander S, Eyles DW, McGrath JJ, Burne THJ. Developmental vitamin D deficiency alters multiple neurotransmitter systems in the neonatal rat brain. *Int J Dev Neurosci* 2017;62:1-7. <https://doi.org/10.1016/j.ijdevneu.2017.07.002>
24. Khassafi N, Zahraei Z, Vahidinia Z, Karimian M, Azami Tameh A. Calcitriol pretreatment attenuates glutamate neurotoxicity by regulating NMDAR and CYP46A1 gene expression in rats subjected to transient middle cerebral artery occlusion. *J Neuropathol Exp Neurol* 2022;81:252-259. <https://doi.org/10.1093/jnen/nlac011>
25. Bhattarai P, Bhattarai JP, Kim MS, Han SK. Non-genomic action of vitamin D3 on N-methyl-D-aspartate and kainate receptor-mediated actions in juvenile gonadotrophin-releasing hormone neurons. *Reprod Fertil Dev* 2017;29:1231-1238. <https://doi.org/10.1071/RD15357>
26. Zong L, Chu P, Huang P, Guo Y, Lv Y. Effect of vitamin D on the learning and memory ability of FGR rat and NMDA receptor expression in hippocampus. *Exp Ther Med* 2017;14:581-586. <https://doi.org/10.3892/etm.2017.4523>
27. Walther DJ, Peter JU, Bashammakh S, Hörtnagl H, Voits M, Fink H, Bader M. Synthesis of serotonin by a second tryptophan hydroxylase isoform. *Science* 2003;299:76. <https://doi.org/10.1126/science.1078197>
28. Kaneko I, Sabir MS, Dussik CM, Whitfield GK, Karrys A, Hsieh JC, Haussler MR, Meyer MB, Pike JW, Jurutka PW. 1,25-Dihydroxyvitamin D regulates expression of the tryptophan hydroxylase 2 and leptin genes: implication for behavioral influences of vitamin D. *FASEB journal: official publication of the Federation of American Societies for Experimental Biology* 2015;29:4023-4035. <https://doi.org/10.1096/fj.14-269811>
29. Patrick RP, Ames BN. Vitamin D hormone regulates serotonin synthesis. Part 1: relevance for autism. *FASEB J* 2014;28:2398-2413. <https://doi.org/10.1096/fj.13-246546>
30. Patrick RP, Ames BN. Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior. *FASEB J* 2015;29:2207-2222. <https://doi.org/10.1096/fj.14-268342>
31. Jiang P, Zhang LH, Cai HL, Li HD, Liu YP, Tang MM, Dang RL, Zhu WY, Xue Y, He X. Neurochemical effects of chronic administration of calcitriol in rats. *Nutrients* 2014;6:6048-6059. <https://doi.org/10.3390/nu6126048>
32. Ali A, Cui X, Eyles D. Developmental vitamin D deficiency and autism: Putative pathogenic mechanisms. *J Steroid Biochem Mol Biol* 2018;175:108-118. <https://doi.org/10.1016/j.jsbmb.2016.12.018>
33. Huiberts LM, Smolders K. Effects of vitamin D on mood and sleep in the healthy population: Interpretations from the serotonergic pathway. *Sleep Med Rev* 2021;55:101379. <https://doi.org/10.1016/j.smrv.2020.101379>

34. Alrefaie Z, Alhayani A. Vitamin D₃ improves decline in cognitive function and cholinergic transmission in prefrontal cortex of streptozotocin-induced diabetic rats. *Behav Brain Res* 2015;287:156-162. <https://doi.org/10.1016/j.bbr.2015.03.050>
35. Alrefaie Z, Moustafa I. Vitamin D₃ favorable outcome on recognition memory and prefrontal cortex expression of choline acetyltransferase and acetylcholinesterase in experimental model of chronic high-fat feeding. *Int J Neurosci* 2020;130:262-269. <https://doi.org/10.1080/00207454.2019.1671839>
36. Rodrigues MV, Gutierrez JM, Carvalho F, Lopes TF, Antunes V, da Costa P, Pereira ME, Schetinger MRC, Morsch VM, de Andrade CM. Protection of cholinergic and antioxidant system contributes to the effect of Vitamin D(3) ameliorating memory dysfunction in sporadic dementia of Alzheimer's type. *Redox Rep* 2019;24:34-40. <https://doi.org/10.1080/13510002.2019.1617514>
37. Rastegar-Moghaddam SH, Hosseini M, Alipour F, Rajabian A, Ebrahimzadeh Bideskan A. The effects of vitamin D on learning and memory of hypothyroid juvenile rats and brain tissue acetylcholinesterase activity and oxidative stress indicators. *Naunyn Schmiedebergs Arch Pharmacol* 2022;395:337-351. <https://doi.org/10.1007/s00210-021-02195-y>
38. Peeyush KT, Savitha B, Sherin A, Anju TR, Jes P, Paulose CS. Cholinergic, dopaminergic and insulin receptors gene expression in the cerebellum of streptozotocin-induced diabetic rats: functional regulation with Vitamin D₃ supplementation. *Pharmacol Biochem Behav* 2010;95:216-222. <https://doi.org/10.1016/j.pbb.2010.01.008>
39. Choi DW. Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. *Trends Neurosci* 1988;11:465-469. [https://doi.org/10.1016/0166-2236\(88\)90200-7](https://doi.org/10.1016/0166-2236(88)90200-7)
40. Brini M, Cali T, Ottolini D, Carafoli E. Neuronal calcium signaling: function and dysfunction. *Cell Mol Life Sci* 2014;71:2787-2814. <https://doi.org/10.1007/s00018-013-1550-7>
41. Brewer LD, Thibault V, Chen KC, Langub MC, Landfield PW, Porter NM. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. *J Neurosci* 2001;21:98-108. <https://doi.org/10.1523/JNEUROSCI.21-01-00098.2001>
42. Eyles D, Almeras L, Benech P, Patatian A, Mackay-Sim A, McGrath J, Féron F. Developmental vitamin D deficiency alters the expression of genes encoding mitochondrial, cytoskeletal and synaptic proteins in the adult rat brain. *J Steroid Biochem Mol Biol* 2007;103:538-545. <https://doi.org/10.1016/j.jsbmb.2006.12.096>
43. Zhu Y, Zhou R, Yang R, Zhang Z, Bai Y, Chang F, Li L, Sokabe M, Goltzman D, Miao D, Chen L. Abnormal neurogenesis in the dentate gyrus of adult mice lacking 1,25-dihydroxy vitamin D₃ (1,25-(OH)₂ D₃). *Hippocampus* 2012;22:421-433. <https://doi.org/10.1002/hipo.20908>
44. Gezen-Ak D, Dursun E, Yilmazer S. The effects of vitamin D receptor silencing on the expression of LVSCC-A1C and LVSCC-A1D and the release of NGF in cortical neurons. *PLoS One* 2011;6:e17553. <https://doi.org/10.1371/journal.pone.0017553>
45. Gooch H, Cui X, Anggono V, Trzaskowski M, Tan MC, Eyles DW, Burne THJ, Jang SE, Mattheisen M, Hougaard DM, Pedersen BN, Cohen A, Mortensen PB, Sah P, McGrath JJ. 1,25-Dihydroxyvitamin D modulates L-type voltage-gated calcium channels in a subset of neurons in the developing mouse prefrontal cortex. *Transl Psychiatry* 2019;9:281. <https://doi.org/10.1038/s41398-019-0626-z>
46. Long W, Fatehi M, Soni S, Panigrahi R, Philippaert K, Yu Y, Kelly R, Boonen B, Barr A, Golec D, Campbell SA, Ondrusova K, Hubert M, Baldwin T, Lemieux MJ, Light PE. Vitamin D is an endogenous partial agonist of the transient receptor potential vanilloid 1 channel. *J Physiol* 2020;598:4321-4338. <https://doi.org/10.1113/JP279961>
47. Berridge MJ. Vitamin D, reactive oxygen species and calcium signalling in ageing and disease. *Philos Trans R Soc Lond B Biol Sci* 2016;371. <https://doi.org/10.1098/rstb.2015.0434>
48. Menegaz D, Barrientos-Duran A, Kline A, Silva FR, Norman AW, Mizwicki MT, Zanello LP. 1alpha,25(OH)₂-Vitamin D₃ stimulation of secretion via chloride channel activation in Sertoli cells. *J Steroid Biochem Mol Biol* 2010;119:127-134. <https://doi.org/10.1016/j.jsbmb.2010.01.011>
49. Menegaz D, Mizwicki MT, Barrientos-Duran A, Chen N, Henry HL, Norman AW. Vitamin D receptor (VDR) regulation of voltage-gated chloride channels by ligands preferring a VDR-alternative pocket (VDR-AP). *Mol Endocrinol* 2011;25:1289-1300. <https://doi.org/10.1210/me.2010-0442>

50. Alexianu ME, Robbins E, Carswell S, Appel SH. 1 α , 25 dihydroxyvitamin D₃-dependent up-regulation of calcium-binding proteins in motoneuron cells. *J Neurosci Res* 1998;51:58-66. [https://doi.org/10.1002/\(SICI\)1097-4547\(19980101\)51:1<58::AID-JNR6>3.0.CO;2-K](https://doi.org/10.1002/(SICI)1097-4547(19980101)51:1<58::AID-JNR6>3.0.CO;2-K)
51. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. *Annu Rev Neurosci* 2001;24:677-736. <https://doi.org/10.1146/annurev.neuro.24.1.677>
52. Wion D, MacGrogan D, Neveu I, Jehan F, Houlgatte R, Brachet P. 1,25-Dihydroxyvitamin D₃ is a potent inducer of nerve growth factor synthesis. *J Neurosci Res* 1991;28:110-114. <https://doi.org/10.1002/jnr.490280111>
53. Neveu I, Naveilhan P, Jehan F, Baudet C, Wion D, De Luca HF, Brachet P. 1,25-dihydroxyvitamin D₃ regulates the synthesis of nerve growth factor in primary cultures of glial cells. *Brain Res Mol Brain Res* 1994;24:70-76. [https://doi.org/10.1016/0169-328X\(94\)90119-8](https://doi.org/10.1016/0169-328X(94)90119-8)
54. Hahn M, Lorez H, Fischer G. Effect of calcitriol in combination with corticosterone, interleukin-1 β , and transforming growth factor- β 1 on nerve growth factor secretion in an astroglial cell line. *Journal of neurochemistry* 1997;69:102-109. <https://doi.org/10.1046/j.1471-4159.1997.69010102.x>
55. Cornet A, Baudet C, Neveu I, Baron-Van Evercooren A, Brachet P, Naveilhan P. 1,25-Dihydroxyvitamin D₃ regulates the expression of VDR and NGF gene in Schwann cells in vitro. *J Neurosci Res* 1998;53:742-746. [https://doi.org/10.1002/\(SICI\)1097-4547\(19980915\)53:6<742::AID-JNR11>3.0.CO;2-#](https://doi.org/10.1002/(SICI)1097-4547(19980915)53:6<742::AID-JNR11>3.0.CO;2-#)
56. Brown J, Bianco JJ, McGrath JJ, Eyles DW. 1,25-dihydroxyvitamin D₃ induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. *Neurosci Lett* 2003;343:139-143. [https://doi.org/10.1016/S0304-3940\(03\)00303-3](https://doi.org/10.1016/S0304-3940(03)00303-3)
57. Saporito MS, Wilcox HM, Hartpence KC, Lewis ME, Vaught JL, Carswell S. Pharmacological induction of nerve growth factor mRNA in adult rat brain. *Exp Neurol* 1993;123:295-302. <https://doi.org/10.1006/exnr.1993.1162>
58. Shirazi HA, Rasouli J, Ciric B, Rostami A, Zhang GX. 1,25-Dihydroxyvitamin D₃ enhances neural stem cell proliferation and oligodendrocyte differentiation. *Exp Mol Pathol* 2015;98:240-245. <https://doi.org/10.1016/j.yexmp.2015.02.004>
59. Mansouri F, Ghanbari H, Marefati N, Arab Z, Salmani H, Beheshti F, Hosseini M. Protective effects of vitamin D on learning and memory deficit induced by scopolamine in male rats: the roles of brain-derived neurotrophic factor and oxidative stress. *Naunyn Schmiedebergs Arch Pharmacol* 2021;394:1451-1466. <https://doi.org/10.1007/s00210-021-02062-w>
60. Xu Y, Liang L. Vitamin D₃/vitamin D receptor signaling mitigates symptoms of post-stroke depression in mice by upregulating hippocampal BDNF expression. *Neurosci Res* 2021;170:306-313. <https://doi.org/10.1016/j.neures.2020.08.002>
61. Khairy EY, Attia MM. Protective effects of vitamin D on neurophysiologic alterations in brain aging: role of brain-derived neurotrophic factor (BDNF). *Nutr Neurosci* 2021;24:650-659. <https://doi.org/10.1080/1028415X.2019.1665854>
62. Hawes JE, Tesic D, Whitehouse AJ, Zosky GR, Smith JT, Wyrwoll CS. Maternal vitamin D deficiency alters fetal brain development in the BALB/c mouse. *Behav Brain Res* 2015;286:192-200. <https://doi.org/10.1016/j.bbr.2015.03.008>
63. Quialheiro A, E DO, Moreira JD, Xavier AJ, Peres MA. The association between vitamin D and BDNF on cognition in older adults in Southern Brazil. *Rev Saude Publica* 2023;56:109. <https://doi.org/10.11606/s1518-8787.2022056004134>
64. Neveu I, Naveilhan P, Baudet C, Brachet P, Metsis M. 1,25-dihydroxyvitamin D₃ regulates NT-3, NT-4 but not BDNF mRNA in astrocytes. *Neuroreport* 1994;6:124-126. <https://doi.org/10.1097/00001756-199412300-00032>
65. Jiang P, Zhang WY, Li HD, Cai HL, Liu YP, Chen LY. Stress and vitamin D: altered vitamin D metabolism in both the hippocampus and myocardium of chronic unpredictable mild stress exposed rats. *Psychoneuroendocrinology* 2013;38:2091-2098. <https://doi.org/10.1016/j.psyneuen.2013.03.017>
66. Banerjee SP, Snyder SH, Cuatrecasas P, Greene LA. Binding of nerve growth factor receptor in sympathetic ganglia. *Proc Natl Acad Sci U S A* 1973;70:2519-2523. <https://doi.org/10.1073/pnas.70.9.2519>
67. Frade JM, Barde YA. Nerve growth factor: two receptors, multiple functions. *Bioessays* 1998;20:137-145. [https://doi.org/10.1002/\(SICI\)1521-1878\(199802\)20:2<137::AID-BIES6>3.0.CO;2-Q](https://doi.org/10.1002/(SICI)1521-1878(199802)20:2<137::AID-BIES6>3.0.CO;2-Q)

68. Barker PA. p75NTR is positively promiscuous: novel partners and new insights. *Neuron* 2004;42:529-533. <https://doi.org/10.1016/j.neuron.2004.04.001>
69. Baas D, Prüfer K, Ittel ME, Kuchler-Bopp S, Labourdette G, Sarliève LL, Brachet P. Rat oligodendrocytes express the vitamin D(3) receptor and respond to 1,25-dihydroxyvitamin D(3). *Glia* 2000;31:59-68. [https://doi.org/10.1002/\(SICI\)1098-1136\(200007\)31:1<59::AID-GLIA60>3.0.CO;2-Y](https://doi.org/10.1002/(SICI)1098-1136(200007)31:1<59::AID-GLIA60>3.0.CO;2-Y)
70. Naveilhan P, Neveu I, Baudet C, Funakoshi H, Wion D, Brachet P, Metsis M. 1,25-Dihydroxyvitamin D3 regulates the expression of the low-affinity neurotrophin receptor. *Brain Res Mol Brain Res* 1996;41:259-268. [https://doi.org/10.1016/0169-328X\(96\)00103-9](https://doi.org/10.1016/0169-328X(96)00103-9)
71. Sanchez B, Lopez-Martin E, Segura C, Labandeira-Garcia JL, Perez-Fernandez R. 1,25-Dihydroxyvitamin D(3) increases striatal GDNF mRNA and protein expression in adult rats. *Brain Res Mol Brain Res* 2002;108:143-146. [https://doi.org/10.1016/S0169-328X\(02\)00545-4](https://doi.org/10.1016/S0169-328X(02)00545-4)
72. Orme RP, Bhangal MS, Fricker RA. Calcitriol imparts neuroprotection in vitro to midbrain dopaminergic neurons by upregulating GDNF expression. *PLoS One* 2013;8:e62040. <https://doi.org/10.1371/journal.pone.0062040>
73. Naveilhan P, Neveu I, Wion D, Brachet P. 1,25-Dihydroxyvitamin D3, an inducer of glial cell line-derived neurotrophic factor. *Neuroreport* 1996;7:2171-2175. <https://doi.org/10.1097/00001756-199609020-00023>
74. Smith MP, Fletcher-Turner A, Yurek DM, Cass WA. Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine. *Neurochem Res* 2006;31:533-539. <https://doi.org/10.1007/s11064-006-9048-4>
75. Cui X, Pertile R, Liu P, Eyles DW. Vitamin D regulates tyrosine hydroxylase expression: N-cadherin a possible mediator. *Neuroscience* 2015;304:90-100. <https://doi.org/10.1016/j.neuroscience.2015.07.048>
76. Tague SE, Smith PG. Vitamin D deficiency leads to sensory and sympathetic denervation of the rat synovium. *Neuroscience* 2014;279:77-93. <https://doi.org/10.1016/j.neuroscience.2014.08.035>
77. Sakai S, Suzuki M, Tashiro Y, Tanaka K, Takeda S, Aizawa K, Hirata M, Yogo K, Endo K. Vitamin D receptor signaling enhances locomotive ability in mice. *J Bone Miner Res* 2015;30:128-136. <https://doi.org/10.1002/jbmr.2317>
78. Bayat M, Kohlmeier KA, Haghani M, Haghghi AB, Khalili A, Bayat G, Hooshmandi E, Shabani M. Co-treatment of vitamin D supplementation with enriched environment improves synaptic plasticity and spatial learning and memory in aged rats. *Psychopharmacology (Berl)* 2021;238:2297-2312. <https://doi.org/10.1007/s00213-021-05853-4>
79. Wu S, Grieff M, Brown AJ. Regulation of renal vitamin D-24-hydroxylase by phosphate: effects of hypophysectomy, growth hormone and insulin-like growth factor I. *Biochem Biophys Res Commun* 1997;233:813-817. <https://doi.org/10.1006/bbrc.1997.6541>
80. Gómez JM. The role of insulin-like growth factor I components in the regulation of vitamin D. *Curr Pharm Biotechnol* 2006;7:125-132. <https://doi.org/10.2174/138920106776597621>
81. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. *J Biol Chem* 2005;280:2543-2549. <https://doi.org/10.1074/jbc.M408903200>
82. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. *J Am Soc Nephrol* 2006;17:1305-1315. <https://doi.org/10.1681/ASN.2005111185>
83. Keisala T, Minasyan A, Lou YR, Zou J, Kalueff AV, Pyykkö I, Tuohimaa P. Premature aging in vitamin D receptor mutant mice. *J Steroid Biochem Mol Biol* 2009;115:91-97. <https://doi.org/10.1016/j.jsbmb.2009.03.007>
84. Xu Y, Sun Z. Molecular basis of Klotho: from gene to function in aging. *Endocr Rev* 2015;36:174-193. <https://doi.org/10.1210/er.2013-1079>
85. Erben RG. Update on FGF23 and Klotho signaling. *Mol Cell Endocrinol* 2016;432:56-65. <https://doi.org/10.1016/j.mce.2016.05.008>
86. Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. *Mol Endocrinol* 2003;17:2393-2403. <https://doi.org/10.1210/me.2003-0048>

87. Obradovic D, Zanca C, Vogl A, Trümbach D, Deussing J, Condorelli G, Rein T. Vitamin D3 signalling in the brain enhances the function of phosphoprotein enriched in astrocytes--15 kD (PEA-15). *J Cell Mol Med* 2009;13:3315-3328. <https://doi.org/10.1111/j.1582-4934.2009.00753.x>
88. Shen Z, Zhang X, Tang J, Kasiappan R, Jinwal U, Li P, Hann S, Nicosia SV, Wu J, Zhang X, Bai W. The coupling of epidermal growth factor receptor down regulation by 1alpha,25-dihydroxyvitamin D3 to the hormone-induced cell cycle arrest at the G1-S checkpoint in ovarian cancer cells. *Mol Cell Endocrinol* 2011;338:58-67. <https://doi.org/10.1016/j.mce.2011.02.023>
89. Peitl V, Silić A, Orlović I, Vidrih B, Crnković D, Karlović D. Vitamin D and Neurotrophin Levels and Their Impact on the Symptoms of Schizophrenia. *Neuropsychobiology* 2020;79:179-185. <https://doi.org/10.1159/000504577>
90. Veenstra TD, Windebank AJ, Kumar R. 1,25-dihydroxyvitamin D3 regulates the expression of N-myc, c-myc, protein kinase C, and transforming growth factor-beta2 in neuroblastoma cells. *Biochem Biophys Res Commun* 1997;235:15-18. <https://doi.org/10.1006/bbrc.1997.6718>
91. Lai CS, Fisher SE, Hurst JA, Vargha-Khadem F, Monaco AP. A forkhead-domain gene is mutated in a severe speech and language disorder. *Nature* 2001;413:519-523. <https://doi.org/10.1038/35097076>
92. Taniura H, Ito M, Sanada N, Kuramoto N, Ohno Y, Nakamichi N, Yoneda Y. Chronic vitamin D3 treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons. *J Neurosci Res* 2006;83:1179-1189. <https://doi.org/10.1002/jnr.20824>
93. Kouba BR, Torrá A, Camargo A, Rodrigues ALS. The antidepressant-like effect elicited by vitamin D(3) is associated with BDNF/TrkB-related synaptic protein synthesis. *Metab Brain Dis* 2023;38:601-611. <https://doi.org/10.1007/s11011-022-01115-0>
94. Patel P, Shah J. Vitamin D(3) supplementation ameliorates cognitive impairment and alters neurodegenerative and inflammatory markers in scopolamine induced rat model. *Metab Brain Dis* 2022;37:2653-2667. <https://doi.org/10.1007/s11011-022-01086-2>
95. Saad El-Din S, Rashed L, Medhat E, Emad Aboulhoda B, Desoky Badawy A, Mohammed ShamsEldeen A, Abdelgwad M. Active form of vitamin D analogue mitigates neurodegenerative changes in Alzheimer's disease in rats by targeting Keap1/Nrf2 and MAPK-38p/ERK signaling pathways. *Steroids* 2020;156:108586. <https://doi.org/10.1016/j.steroids.2020.108586>
96. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Müller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. *Nature* 1987;325:733-736. <https://doi.org/10.1038/325733a0>
97. Grimm MO, Lehmann J, Mett J, Zimmer VC, Grösgen S, Stahlmann CP, Hundsdörfer B, Haupenthal VJ, Rothhaar TL, Herr C, Bals R, Grimm HS, Hartmann T. Impact of Vitamin D on amyloid precursor protein processing and amyloid- β peptide degradation in Alzheimer's disease. *Neurodegener Dis* 2014;13:75-81. <https://doi.org/10.1159/000355462>
98. Grimm MOW, Thiel A, Lauer AA, Winkler J, Lehmann J, Regner L, Nelke C, Janitschke D, Benoist C, Streidenberger O, Stötzel H, Endres K, Herr C, Beisswenger C, Grimm HS, Bals R, Lammert F, Hartmann T. Vitamin D and Its Analogues Decrease Amyloid- β (A β) Formation and Increase A β -Degradation. *Int J Mol Sci* 2017;18. <https://doi.org/10.3390/ijms18122764>
99. Jia J, Hu J, Huo X, Miao R, Zhang Y, Ma F. Effects of vitamin D supplementation on cognitive function and blood A β -related biomarkers in older adults with Alzheimer's disease: a randomised, double-blind, placebo-controlled trial. *J Neurol Neurosurg Psychiatry* 2019;90:1347-1352. <https://doi.org/10.1136/jnnp-2018-320199>
100. Zhang Y, Ji W, Zhang S, Gao N, Xu T, Wang X, Zhang M. Vitamin D inhibits the early aggregation of α -synuclein and modulates exocytosis revealed by electrochemical measurements. *Angew Chem Int Ed Engl* 2022;61:e202111853. <https://doi.org/10.1002/anie.202111853>
101. Rcom-H'cheo-Gauthier AN, Meedeniya AC, Pountney DL. Calcipotriol inhibits α -synuclein aggregation in SH-SY5Y neuroblastoma cells by a Calbindin-D28k-dependent mechanism. *J Neurochem* 2017;141:263-274. <https://doi.org/10.1111/jnc.13971>

102. Cataldi S, Arcuri C, Hunot S, Mecca C, Codini M, Laurenti ME, Ferri I, Loreti E, Garcia-Gil M, Traina G, Conte C, Ambesi-Impiomato FS, Beccari T, Curcio F, Albi E. Effect of Vitamin D in HN9.10e Embryonic hippocampal cells and in hippocampus from MPTP-induced parkinson's disease mouse model. *Front Cell Neurosci* 2018;12:31. <https://doi.org/10.3389/fncel.2018.00031>
103. Farhangi MA, Mesgari-Abbasi M, Nameni G, Hajilulian G, Shahabi P. The effects of vitamin D administration on brain inflammatory markers in high fat diet induced obese rats. *BMC Neurosci* 2017;18:81. <https://doi.org/10.1186/s12868-017-0400-1>
104. Zhang D, Li M, Dong Y, Zhang X, Liu X, Chen Z, Zhu Y, Wang H, Liu X, Zhu J, Shen Y, Korner H, Ying S, Fang S, Shen Y. $1\alpha,25$ -Dihydroxyvitamin D₃ up-regulates IL-34 expression in SH-SY5Y neural cells. *Innate Immun* 2017;23:584-591. <https://doi.org/10.1177/1753425917725391>
105. Peterson CA, Heffernan ME. Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. *J Inflamm (Lond)* 2008;5:10. <https://doi.org/10.1186/1476-9255-5-10>
106. Almeida Moreira Leal LK, Lima LA, Alexandre de Aquino PE, Costa de Sousa JA, Jataí Gadelha CV, Felício Calou IB, Pereira Lopes MJ, Viana Lima FA, Tavares Neves KR, Matos de Andrade G, Socorro de Barros Viana G. Vitamin D (VD₃) antioxidative and anti-inflammatory activities: Peripheral and central effects. *Eur J Pharmacol* 2020;879:173099. <https://doi.org/10.1016/j.ejphar.2020.173099>
107. Miroliaee AE, Salamzadeh J, Shokouhi S, Sahraei Z. The study of vitamin D administration effect on CRP and Interleukin-6 as prognostic biomarkers of ventilator associated pneumonia. *J Crit Care* 2018;44:300-305. <https://doi.org/10.1016/j.jcrc.2017.08.040>
108. Bhat M, Ismail A. Vitamin D treatment protects against and reverses oxidative stress induced muscle proteolysis. *J Steroid Biochem Mol Biol* 2015;152:171-179. <https://doi.org/10.1016/j.jsbmb.2015.05.012>
109. Garcion E, Sindji L, Leblondel G, Brachet P, Darcy F. $1,25$ -dihydroxyvitamin D₃ regulates the synthesis of gamma-glutamyl transpeptidase and glutathione levels in rat primary astrocytes. *J Neurochem* 1999;73:859-866. <https://doi.org/10.1046/j.1471-4159.1999.0730859.x>
110. Eyles DW. Vitamin D: Brain and Behavior. *JBMR Plus* 2021;5:e10419. <https://doi.org/10.1002/jbm4.10419>
111. Groves NJ, Burne THJ. The impact of vitamin D deficiency on neurogenesis in the adult brain. *Neural Regen Res* 2017;12:393-394. <https://doi.org/10.4103/1673-5374.202936>
112. Thiel A, Hermanns C, Lauer AA, Reichrath J, Erhardt T, Hartmann T, Grimm MOW, Grimm HS. Vitamin D and its analogues: from differences in molecular mechanisms to potential benefits of adapted use in the treatment of alzheimer's disease. *Nutrients* 2023;15. <https://doi.org/10.3390/nu15071684>
113. Sintzel MB, Rametta M, Reder AT. Vitamin D and Multiple Sclerosis: A Comprehensive Review. *Neurol Ther* 2018;7:59-85. <https://doi.org/10.1007/s40120-017-0086-4>
114. Habib AM, Nagi K, Thillaiappan NB, Sukumaran V, Akhtar S. Vitamin D and its potential interplay with pain signaling pathways. *Front Immunol* 2020;11:820. <https://doi.org/10.3389/fimmu.2020.00820>
115. Rihal V, Khan H, Kaur A, Singh TG, Abdel-Daim MM. Therapeutic and mechanistic intervention of vitamin D in neuropsychiatric disorders. *Psychiatry Res* 2022;317:114782. <https://doi.org/10.1016/j.psychres.2022.114782>
116. Saedisomeolia A, Samadi M, Gholami F, Seyedi M, Effatpanah M, Hashemi R, Abdolahi M, Honarvar NM. Vitamin D's molecular action mechanism in attention-deficit/ hyperactivity disorder: a review of evidence. *CNS Neurol Disord Drug Targets* 2018;17:280-290. <https://doi.org/10.2174/1871527317666180501111627>
117. Camu W, Tremblier B, Plassot C, Alphantery S, Salsac C, Pageot N, Juntas-Morales R, Scamps F, Daures JP, Raoul C. Vitamin D confers protection to motoneurons and is a prognostic factor of amyotrophic lateral sclerosis. *Neurobiol Aging* 2014;35:1198-1205. <https://doi.org/10.1016/j.neurobiolaging.2013.11.005>
118. Anwar MJ, Alenezi SK, Alhowail AH. Molecular insights into the pathogenic impact of vitamin D deficiency in neurological disorders. *Biomed Pharmacother* 2023;162:114718. <https://doi.org/10.1016/j.biopha.2023.114718>
119. Lo CS, Kiang KM, Leung GK. Anti-tumor effects of vitamin D in glioblastoma: mechanism and therapeutic implications. *Lab Invest* 2022;102:118-125. <https://doi.org/10.1038/s41374-021-00673-8>
120. Casseb GAS, Kaster MP, Rodrigues ALS. Potential role of vitamin D for the management of depression and anxiety. *CNS Drugs* 2019;33:619-637. <https://doi.org/10.1007/s40263-019-00640-4>

-
121. Manjari SKV, Maity S, Poornima R, Yau SY, Vaishali K, Stellwagen D, Komal P. Restorative action of vitamin D3 on motor dysfunction through enhancement of neurotrophins and antioxidant expression in the striatum. *Neuroscience* 2022;492:67-81. <https://doi.org/10.1016/j.neuroscience.2022.03.039>
 122. Berridge MJ. Vitamin D and depression: cellular and regulatory mechanisms. *Pharmacol Rev* 2017;69:80-92. <https://doi.org/10.1124/pr.116.013227>
 123. Schlögl M, Holick MF. Vitamin D and neurocognitive function. *Clin Interv Aging* 2014;9:559-568. <https://doi.org/10.2147/CIA.S51785>
 124. Wu Y, Cai Y, Liu M, Zhu D, Guan Y. The potential immunoregulatory roles of vitamin D in neuromyelitis optica spectrum disorder. *Mult Scler Relat Disord* 2020;43:102156. <https://doi.org/10.1016/j.msard.2020.102156>
 125. Stewart AE, Roecklein KA, Tanner S, Kimlin MG. Possible contributions of skin pigmentation and vitamin D in a polyfactorial model of seasonal affective disorder. *Med Hypotheses* 2014;83:517-525. <https://doi.org/10.1016/j.mehy.2014.09.010>
 126. O'Tuathaigh CMP, Moran PM, Zhen XC, Waddington JL. Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies. *Br J Pharmacol* 2017;174:3173-3190. <https://doi.org/10.1111/bph.13938>
 127. de Oliveira DL, Hirotsu C, Tufik S, Andersen ML. The interfaces between vitamin D, sleep and pain. *J Endocrinol* 2017;234:R23-r36. <https://doi.org/10.1530/JOE-16-0514>
 128. Quraishi SA, Camargo CA, Jr. Vitamin D in acute stress and critical illness. *Curr Opin Clin Nutr Metab Care* 2012;15:625-634. <https://doi.org/10.1097/MCO.0b013e328358fc2b>
 129. Pál É, Ungvári Z, Benyó Z, Várbíró S. Role of vitamin D deficiency in the pathogenesis of cardiovascular and cerebrovascular diseases. *Nutrients* 2023;15. <https://doi.org/10.3390/nu15020334>
-